Recent developments with Mineralys Therapeutics Inc (MLYS) have led to the company’s beta value being reach 1.50 cents.
On Tuesday, Mineralys Therapeutics Inc (NASDAQ: MLYS) was -5.30% drop from the session before settling in for the closing price of $9.25. A 52-week range